Inactive Instrument

EXOPHARM

Equities

EX1

AU0000030975

Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2021

August 29, 2021 at 11:17 pm

Exopharm Limited announced earnings results for the full year ended June 30, 2021. For the full year, the company announced net loss was AUD 8.468 million compared to AUD 5.278 million a year ago. Basic loss per share from continuing operations was AUD 0.0648 compared to AUD 0.0562 a year ago.

Latest news about EXOPHARM

Tryp Therapeutics Inc. completed the acquisition of Exopharm Limited in a reverse merger transaction.	04-30	CI
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-26	CI
Exopharm to Cut CEO Role Amid Cost Reductions	11-28	MT
Exopharm Limited Announces Ian Dixon's Employment as CEO Expects to End in Early Calendar Year 2024	11-27	CI
Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2023	28/08/23	CI
Exopharm Limited Announces Executive Changes	22/06/23	CI
Exopharm Achieves Initial Success With Exosome Products; Shares Fall 21%	28/04/23	MT
Exopharm Secures R&D Cash Loan Advance from Radium Capital	09/03/23	MT
Exopharm Limited announced that it has received AUD 1 million in funding	08/03/23	CI
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2022	26/02/23	CI
Exopharm Limited Announces Board Changes	22/02/23	CI
Exopharm Limited announced that it expects to receive AUD 0.6 million in funding	12/02/23	CI
Exopharm Limited Announces Resignation of Elizabeth McGregor as Non-Executive Director	20/12/22	CI
Sartorius BIA Separations and Exopharm Ltd Testing the Synergy of Exopharm's Patented LEAP Technology Together with Bia's Unique Cim (Convective Interaction Media) Monolith Chromatography for Improved Large- Scale Exosome Production and Commercialization	16/11/22	CI
Exopharm Limited Will Commence LEAP Technology Transfer to AIRM under MSA	13/11/22	CI
Exopharm Receives $2.6 Million R&D Tax Rebate	27/10/22	MT
Exopharm Says Drug Product Safe After Animal Testing	28/09/22	MT
Exopharm Limited Announces Study Results Indicate Exosomes Safe for Clinical Pursuit	27/09/22	CI
Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2022	30/08/22	CI
Exopharm Limited Auditor Raises 'Going Concern' Doubt	29/08/22	CI
Exopharm Enters Loan Agreement for Early Access to R&D Tax Rebate	16/06/22	MT
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2021	25/02/22	CI
Exopharm, AIRM Enter Collaborative Services Agreement	31/01/22	MT
Exopharm Limited Signs Master Collaborative Services Agreement with the Astellas Institute for Regenerative Medicine	30/01/22	CI
Exopharm Gets US Patent for Drug Delivery Technology	22/12/21	MT

Chart EXOPHARM

Duration

Period

More charts

Company Profile

Tryptamine Therapeutics Limited, formerly Exopharm Limited, is an Australia-based company involved in advancing genetic medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug delivery. The Company invests in biopharmaceutical drug development. The Company is engaged in exosome technology and holds a portfolio of intellectual property and know-how related to exosomes and the manufacture of exosomes. The Companyâs exosome technologies solve the needs for the success of exosome medicines, LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies. The Company is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome delivery for their own products.

Sector

More about the company